Potential Efficacy of Janus Kinase Inhibitors in the Treatment of a Patient With Coexisting Peripheral and Axial Spondyloarthritis and Ulcerative Colitis

J Rheumatol. 2024 May 1:jrheum.2024-0055. doi: 10.3899/jrheum.2024-0055. Online ahead of print.ABSTRACTTumor necrosis factor inhibitors are effective and recommended in treating patients with coexisting spondyloarthritis (SpA) and ulcerative colitis (UC); however, the evidence of their superiority over other drugs is insufficient.1 Although Janus kinase inhibitors (JAKi) have shown effectiveness in treating UC and psoriatic arthritis, there are no reports of treating coexisting SpA and UC with JAKi monotherapy.PMID:38692666 | DOI:10.3899/jrheum.2024-0055
Source: J Rheumatol - Category: Rheumatology Authors: Source Type: research